Clinical trial
Evaluating Atorvastatin With Omega-3 Fatty Acids in Cardiovascular Risk…
NCT00141232 · Pfizer's Upjohn has merged with Mylan to form Viatris Inc., Industry · Completed
Key facts
| NCT number | NCT00141232 |
|---|---|
| Title | Evaluating Atorvastatin With Omega-3 Fatty Acids in Cardiovascular Risk Reduction in Patients With Type 2 Diabetes |
| Official title | A Multicentre, Randomised, Double Blind Placebo Controlled Trial Evaluating Atorvastatin in Factorial With Omega-3 Fatty Acids Cardiovascular Risk Reduction in Patients With Type 2 Diabetes |
| Acronym | AFORRD |
| Lead sponsor | Pfizer's Upjohn has merged with Mylan to form Viatris Inc., Industry |
| Collaborators | Churchill Hospital |
| Status | Completed |
| Phase | Phase 4 |
| Study type | Interventional |
| Conditions | Diabetes, Type 2 |
| Intervention type | Drug |
| Interventions | Atorvastatin and Omega-3 fatty acids |
| Enrollment | 810 |
| Start date | Nov 1, 2004 |
| Completion | Jul 1, 2006 |
| First posted | Sep 1, 2005 |
| Last update posted | Feb 18, 2021 |
| Countries | United Kingdom |
At a glance
- 10–99 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: